| 0.096 0.003 (3.17%) | 12-29 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.11  |
1-year : | 0.13 |
| Resists | First : | 0.09 |
Second : | 0.11 |
| Pivot price | 0.07 |
|||
| Supports | First : | 0.04 |
Second : | 0 |
| MAs | MA(5) : | 0.09 |
MA(20) : | 0.07 |
| MA(100) : | 0.06 |
MA(250) : | 0.14  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 95.6 |
D(3) : | 95.2 |
| RSI | RSI(14): 66.3 |
|||
| 52-week | High : | 0.72 | Low : | 0 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ APTX ] has closed below upper band by 18.9%. Bollinger Bands are 408.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.1 - 0.1 | 0.1 - 0.1 |
| Low: | 0.09 - 0.09 | 0.09 - 0.09 |
| Close: | 0.1 - 0.1 | 0.1 - 0.1 |
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
Tue, 23 Apr 2024
Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO - Business Wire
Wed, 19 Apr 2023
Bellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSK - Nasdaq
Mon, 17 Apr 2023
Prometheus (RXDX) Stock Surges 70% on Buyout Offer From Merck - Nasdaq
Tue, 14 Mar 2023
Seagen (SGEN) Set to be Acquired by Pfizer for $43 B, Stock Up - Nasdaq
Tue, 21 Feb 2023
Aptinyx: Readout Imminent For NYX-458 In Parkinson's Disease Dementia (NASDAQ:APTX) - Seeking Alpha
Tue, 04 Oct 2022
10 Best Stocks to Buy Now According to Jeffrey Diehl’s Adams Street Partners - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 68 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 13.1 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 2,230 (K) |
| Shares Short P.Month | 3,270 (K) |
| EPS | -0.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.27 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -43.6 % |
| Return on Equity (ttm) | -138.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -55 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -0.1 |
| PEG Ratio | 0 |
| Price to Book value | 0.35 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|